Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.39 |
| ▸ | DRD3 | P35462 | 8/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.37 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768562 | 0.92 | MCHR1 (0.41) | DRD2DRD3SIRT5 | |
| SCHEMBL769174 | 0.92 | MCHR1 (0.41) | DRD2DRD3SIRT5 | |
| SCHEMBL768428 | 0.90 | MCHR1 (0.36) | DRD2SIRT5 | |
| SCHEMBL768307 | 0.90 | MCHR1 (0.42) | DRD2 | |
| SCHEMBL768396 | 0.89 | MCHR1 (0.36) | DRD2DRD3SIRT5 | |
| SCHEMBL768715 | 0.89 | MCHR1 (0.35) | DRD2SIRT5 | |
| SCHEMBL768421 | 0.88 | OPRM1 (0.35) | OPRD1SIRT5 | |
| Hydrochloric Acid SCHEMBL768545 | 0.88 | CHRM4 (0.41) | DRD2DRD3CHRM4OPRD1DNMT1 | |
| SCHEMBL768850 | 0.88 | CHRM2 (0.41) | DRD2OPRD1 | |
| SCHEMBL380394 | 0.85 | CHRM2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | DRD2 294/4885DRD3 464/4885CHRM4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.